Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL871031 | 1.00 | SCN9A (0.43) | SCN9ACYP1A2CYP2D6LMNACYP3A4 | |
| SCHEMBL871030 | 1.00 | SCN9A (0.43) | SCN9ACYP1A2CYP2D6LMNACYP3A4 | |
| Hydrochloric Acid SCHEMBL3040954 | 0.98 | SCN9A (0.42) | SCN9ACYP1A2CYP2D6LMNACYP3A4 | |
| Hydrochloric Acid SCHEMBL3040950 | 0.98 | SCN9A (0.42) | SCN9ACYP1A2CYP2D6LMNACYP3A4 | |
| SCHEMBL22439432 | 0.95 | SCN9A (0.47) | SCN9ACYP1A2CYP2D6LMNACYP3A4 | |
| SCHEMBL6224375 | 0.95 | SCN9A (0.47) | SCN9ACYP1A2CYP2D6LMNACYP3A4 | |
| SCHEMBL1599013 | 0.95 | SCN9A (0.47) | SCN9ACYP1A2CYP2D6LMNACYP3A4 | |
| SCHEMBL3646596 | 0.83 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL3648488 | 0.83 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL3646598 | 0.83 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919507-B2 | N-aroyl cyclic amines | SMITHKLINE BEECHAM LIMITED (GB) | 2011-04-05 | — | — | US | disclosed |
| EP-2155739-B1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-10-06 | — | — | EP | disclosed |
| US-20100222328-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-02 | — | — | US | disclosed |
| US-7741329-B2 | N-aroyl cyclic amines | SMITHKLINE BEECHAM LIMITED (GB) | 2010-06-22 | — | — | US | disclosed |
| EP-2155739-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-02-24 | — | — | EP | disclosed |
| US-20090093478-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.I.C. | 2009-04-09 | — | — | US | disclosed |
| US-20090029986-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. | 2009-01-29 | — | — | US | disclosed |
| US-20090012073-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. | 2009-01-08 | — | — | US | disclosed |
| WO-2008139416-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-11-20 | — | — | WO | disclosed |
| US-7432270-B2 | N-aroyl cyclic amines | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-10-07 | — | — | US | disclosed |
| EP-1956020-A2 | 1-[2-(heterocyclyl-aminomethyl)-piperidin-1-YL]-1-(2-methyl-5-phenyl-heterocyclyl)-methanone derivatives and related compounds as orexin-1 antagonists for the treatment of obesity | SMITHKLINE BEECHAM PLC (GB) | 2008-08-13 | — | — | EP | disclosed |
| US-20080027035-A1 | Dpp-Iv Inhibitors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2008-01-31 | — | — | US | disclosed |
| US-20080027035-A1 | Dpp-Iv Inhibitors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2008-01-31 | — | — | US | disclosed |
| EP-1385845-B1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM PLC (GB) | 2008-01-09 | — | — | EP | disclosed |
| US-20070244328-A1 | Organocatalysts and Methods of Use in Chemical Synthesis | STC.UNM (US) | 2007-10-18 | — | — | US | disclosed |
| EP-1613304-B1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS CH (CH) | 2007-09-12 | — | — | EP | disclosed |
| WO-2005056003-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-06-23 | — | — | WO | disclosed |
| US-20040143115-A1 | N-aroyl cyclic amines | SMITHKLINE BEECHAM LIMITED (GB) | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027035-A1 | Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | SCN9A 1489/4885CYP1A2 666/4885CYP2D6 362/4885 |
| US-20070244328-A1 | Organocatalysts and Methods of Use in Chemical Synthesis | SCO2, CBR1, CBR3 | SCN9A 3249/4885CYP1A2 82/4885CYP2D6 193/4885 |
| US-20090012073-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | SCN9A 804/4885CYP1A2 31/4885CYP2D6 32/4885 |
| US-20090093478-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | SCN9A 804/4885CYP1A2 31/4885CYP2D6 32/4885 |
| US-20090029986-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | SCN9A 804/4885CYP1A2 31/4885CYP2D6 32/4885 |
| US-20100222328-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | HCRTR2, HCRTR1, NPY2R | SCN9A 2234/4885CYP1A2 423/4885CYP2D6 629/4885 |
| US-20040143115-A1 | N-aroyl cyclic amines | HCRTR1, HCRTR2, CNR1 | SCN9A 720/4885CYP1A2 512/4885CYP2D6 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.